Intervention Review

You have full text access to this OnlineOpen article

Antiplatelet agents for chronic kidney disease

  1. Suetonia C Palmer1,*,
  2. Lucia Di Micco2,
  3. Mona Razavian3,
  4. Jonathan C Craig4,5,
  5. Vlado Perkovic3,
  6. Fabio Pellegrini6,7,
  7. Meg J Jardine8,
  8. Angela C Webster4,5,9,
  9. Sophia Zoungas10,
  10. Giovanni FM Strippoli4,5,11,12,13

Editorial Group: Cochrane Renal Group

Published Online: 30 APR 2013

Assessed as up-to-date: 24 JAN 2011

DOI: 10.1002/14651858.CD008834.pub3

How to Cite

Palmer SC, Di Micco L, Razavian M, Craig JC, Perkovic V, Pellegrini F, Jardine MJ, Webster AC, Zoungas S, Strippoli GFM. Antiplatelet agents for chronic kidney disease. Cochrane Database of Systematic Reviews 2013, Issue 4. Art. No.: CD008834. DOI: 10.1002/14651858.CD008834.pub3.

Author Information

  1. 1

    University of Otago Christchurch, Department of Medicine, Christchurch, New Zealand

  2. 2

    University of Naples "Federico II", Division of Nephrology, Naples, Italy

  3. 3

    The George Institute for Global Health, Renal and Metabolic Division, Camperdown, NSW, Australia

  4. 4

    The University of Sydney, Sydney School of Public Health, Sydney, NSW, Australia

  5. 5

    The Children's Hospital at Westmead, Cochrane Renal Group, Centre for Kidney Research, Westmead, NSW, Australia

  6. 6

    Consorzio Mario Negri Sud, Unit of Biostatistics, Department of Clinical Pharmacology and Epidemiology, Santa Maria Imbaro, Italy

  7. 7

    IRCCS "Casa Sollievo della Sofferenza", Unit of Biostatistics, San Giovanni Rotondo (FG), Chieti, Italy

  8. 8

    Concord Repatriation General Hospital, Department of Renal Medicine, Concord, NSW, Australia

  9. 9

    The University of Sydney at Westmead, Centre for Transplant and Renal Research, Westmead Millennium Institute, Westmead, NSW, Australia

  10. 10

    Monash University, School of Public Health and Preventive Medicine, Monash Applied Research Stream, Clayton, VIC, Australia

  11. 11

    University of Bari, Department of Emergency and Organ Transplantation, Bari, Italy

  12. 12

    Mario Negri Sud Consortium, Department of Clinical Pharmacology and Epidemiology, Santa Maria Imbaro, Italy

  13. 13

    Diaverum, Medical-Scientific Office, Lund, Sweden

*Suetonia C Palmer, Department of Medicine, University of Otago Christchurch, 2 Riccarton Ave, PO Box 4345, Christchurch, 8140, New Zealand. suetonia.palmer@otago.ac.nz.

Publication History

  1. Publication Status: Edited (no change to conclusions)
  2. Published Online: 30 APR 2013

SEARCH

References

References to studies included in this review

  1. References to studies included in this review
  2. References to studies excluded from this review
  3. References to ongoing studies
  4. Additional references
  5. References to other published versions of this review
Abdul-Rahman 2007 {published data only}
  • Abdul-Rahman IS, Al-Howaish AK. Warfarin versus aspirin in preventing tunneled hemodialysis catheter thrombosis: a prospective randomized study. Hong Kong Journal of Nephrology 2007;9(1):23-30. [EMBASE: 2007269768]
Anderson 1974 {published data only}
  • Anderson M, Dewar P, Fleming LB, Hacking PM, Morley AR, Murray S, et al. A controlled trial of dipyridamole in human renal transplantation and an assessment of platelet function studies in rejection. Clinical Nephrology 1974;2(3):93-9. [MEDLINE: 4603996]
Andrassy 1974 {published data only}
  • Andrassy K, Malluche H, Bornefeld H, Comberg M, Ritz E, Jesdinsky H, et al. Prevention of p.o. clotting of av. cimino fistulae with acetylsalicyl acid: Results of a prospective double blind study. Klinische Wochenschrift 1974;52(7):348-9. [MEDLINE: 4600820]
CHARISMA Study 2009 {published and unpublished data}
  • Bhatt DL, Flather MD, Hacke W, Berger PB, Black HR, Boden WE, et al. Patients with prior myocardial infarction, stroke, or symptomatic peripheral arterial disease in the CHARISMA trial. Journal of the American College of Cardiology 2007;49(19):1982-8. [MEDLINE: 17498584]
  • Dasgupta A, Steinhubl SR, Bhatt DL, Berger PB, Shao M, Mak KH, et al. Clinical outcomes of patients with diabetic nephropathy randomized to clopidogrel plus aspirin versus aspirin alone (a post hoc analysis of the clopidogrel for high atherothrombotic risk and ischemic stabilization, management, and avoidance [CHARISMA] trial). American Journal of Cardiology 2009;103(10):1359-63. [MEDLINE: 19427428]
  • Wang TH, Bhatt DL, Fox KA, Steinhubl SR, Brennan DM, Hacke W, et al. An analysis of mortality rates with dual-antiplatelet therapy in the primary prevention population of the CHARISMA trial. European Heart Journal 2007;28(18):2200-7. [MEDLINE: 17673448]
Cheng 1998 {published data only}
  • Cheng IK, Fang GX, Wong MC, Ji YL, Chan KW, Yeung HW. A randomized prospective comparison of nadolol, captopril with or without ticlopidine on disease progression in IgA nephropathy. Nephrology 1998;4(1-2):19-26. [EMBASE: 1998205046]
CREDO Study 2008 {published and unpublished data}
  • Best PJ, Steinhubl SR, Berger PB, Dasgupta A, Brennan DM, Szczech LA, et al. The efficacy and safety of short- and long-term dual antiplatelet therapy in patients with mild or moderate chronic kidney disease: results from the Clopidogrel for the Reduction of Events During Observation (CREDO) trial. American Heart Journal 2008;155(4):687-93. [MEDLINE: 18371477]
  • Steinhubl SR, Berger PB, Mann JT 3rd, Fry ET, DeLago A, Wilmer C, et al. Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial. JAMA 2002;288(19):2411-20. [MEDLINE: 12435254]
Creek 1990 {published data only}
  • Creek R. Ticlopidine. Patency of haemodialysis access sites. Guildford Sanofi Winthrop. Internal report 1990.
CURE Study 2007 {published data only (unpublished sought but not used)}
  • Keltai M, Tonelli M, Mann JF, Sitkei E, Lewis BS, Hawken S, et al. Renal function and outcomes in acute coronary syndrome: impact of clopidogrel. European Journal of Cardiovascular Prevention & Rehabilitation 2007;14(2):312-8. [MEDLINE: 17446813]
  • Yusuf S,  Zhao F,  Mehta SR,  Chrolavicius S,  Tognoni G,  Fox KK, et al. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. New England Journal of Medicine 2001;345(7):494-502. [MEDLINE: 11519503]
Dember 2008 {published data only}
  • Dember LM, Beck GJ, Allon M, Delmez JA, Dixon BS, Greenberg A, et al. Effect of clopidogrel on early failure of arteriovenous fistulas for hemodialysis: a randomized controlled trial. JAMA 2008;299(18):2164-71. [MEDLINE: 18477783]
  • Dember LM, Kaufman JS, Beck GJ, Dixon BS, Gassman JJ, Greene T, et al. Design of the Dialysis Access Consortium (DAC) Clopidogrel Prevention of Early AV Fistula Thrombosis Trial. Clinical Trials 2005;2(5):413-22. [MEDLINE: 16317810]
  • Dember LM, Kaufman JS, Beck GJ, Dixon BS, Gassman JJ, Greene T, et al. Dialysis access consortium (DAC) trial design: clopidogrel prevention of early AV fistula thrombosis [abstract]. Journal of the American Society of Nephrology 2002;13(Program & Abstracts):229A.
Dixon 2009 {published data only}
  • Dixon B, Beck G, Meyers C, Kusek J, Feldman H, DAC Study Group. Effect of aspirin (ASA) on primary unassisted graft patency in the dialysis access consortium (DAC) graft trial [abstract]. Journal of the American Society of Nephrology 2008;19(Abstract Issue):256A.
  • Dixon BS, Beck GJ, Dember LM, Depner TA, Gassman JJ, Greene T, et al. Design of the Dialysis Access Consortium (DAC) Aggrenox Prevention Of Access Stenosis Trial. Clinical Trials 2005;2(5):400-12. [MEDLINE: 16317809]
  • Dixon BS, Beck GJ, Vazquez MA, Greenberg A, Delmez JA, Allon M, et al. Dialysis Access Consortium (DAC) Trial design: sustained-release dipyridamole plus aspirin (D/A) to prevent graft failure [abstract]. Journal of the American Society of Nephrology 2002;10(Abstract Issue):232A.
  • Dixon BS, Beck GJ, Vazquez MA, Greenberg A, Delmez JA, Allon M, et al. Effect of dipyridamole plus aspirin on hemodialysis graft patency. New England Journal of Medicine 2009;360(21):2191-201. [MEDLINE: 19458364]
Dodd 1980 {published data only}
  • Dodd NJ, Turney JH, Weston MJ. Ticlopidine preserves vascular access for haemodialysis [abstract 326F]. Proceedings of the VI International Congress of Mediterranean League Against Thrombosis. 1980.
Donadio 1984 {published data only}
  • Donadio JV Jr, Anderson CF, Mitchell JC 3rd, Holley KH, Ilstrup DM, Fuster V, et al. Membranoproliferative glomerulonephritis. A prospective clinical trial of platelet-inhibitor therapy. New England Journal of Medicine 1984;310(22):1421-6. [MEDLINE: 6371535]
Ell 1982 {published and unpublished data}
  • Ell S, Mihindukulasuriya JC, O'Brien JR, Polak A, Vernham G. Ticlopidine in the prevention of blockage of fistulae and shunts. Haemostasis 1982; Vol. 12:180.
EPIC Study 1994 {published data only}
  • Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty. The EPIC Investigation. New England Journal of Medicine 1994;330(14):956-61. [MEDLINE: 8121459]
  • Topol EJ, Califf RM, Weisman HF, Ellis SG, Tcheng JE, Worley S, et al. Randomised trial of coronary intervention with antibody against platelet IIb/IIIa integrin for reduction of clinical restenosis: results at six months. The EPIC Investigators. Lancet 1994;343(8902):881-6. [MEDLINE: 7908357]
  • Topol EJ, Ferguson JJ, Weisman HF, Tcheng JE, Ellis SG, Kleiman NS, et al. Long-term protection from myocardial ischemic events in a randomized trial of brief integrin beta3 blockade with percutaneous coronary intervention. EPIC Investigator Group. Evaluation of Platelet IIb/IIIa Inhibition for Prevention of Ischemic Complication. JAMA 1997;278(6):479-84. [MEDLINE: 9256222]
EPILOG Study 1997 {unpublished data only}
  • Platelet glycoprotein IIb/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularization. The EPILOG Investigators. New England Journal of Medicine 1997;336(24):1689-96. [MEDLINE: 9182212]
  • Lincoff AM, Tcheng JE, Califf RM, Kereiakes DJ, Kelly TA, Timmis GC, et al. Sustained suppression of ischemic complications of coronary intervention by platelet GP IIb/IIIa blockade with abciximab. One-year outcome in the EPILOG trial. Circulation 1999;99(15):1951-8. [MEDLINE: 10208997]
EPISTENT Study 1998 {unpublished data only}
  • EPISTENT Investigators. Randomised placebo-controlled and balloon-angioplasty-controlled trial to assess safety of coronary stenting with use of platelet glycoprotein-IIb/IIIa blockade. Lancet 1998;352(9122):87-92. [MEDLINE: 9672272]
  • Topol EJ, Mark DB, Lincoff AM, Cohen E, Burton J, Kleiman N, et al. Outcomes at 1 year and economic implications of platelet glycoprotein IIb/IIIa blockade in patients undergoing coronary stenting: results from a multicentre randomised trial. EPISTENT Investigators. Evaluation of Platelet IIb/IIIa Inhibitor for Stenting. Lancet 1999;354(9195):2019-24. [MEDLINE: 10636365]
ETDRS 1992 {unpublished data only}
  • Aspirin effects on mortality and morbidity in patients with diabetes mellitus. Early Treatment Diabetic Retinopathy Study report 14. ETDRS Investigators. JAMA 1992;268(10):1292-300. [MEDLINE: 1507375]
Fiskerstrand 1985 {published data only}
Frascà 1986 {published data only}
  • Frascà GM, Vangelista A, Raimondi C, Bonomini V. Prevention of vascular graft lesions in renal transplant recipients with a new antithrombotic agent (Defibrotide): a controlled study. Life Support System 1986;4(3):231-7. [MEDLINE: 3537545]
Frascà 1997 {published data only}
  • Bonomini V, Vangelista A, Stefoni S, Scolari MP, Frascà GM, Raimondi C. Use of defibrotide in renal transplantation in man. Haemostasis 1986;16 Suppl 1:48-50. [MEDLINE: 3519383]
  • Frascà GM, Cianciolo G. A clinical trial with defibrotide in IgA nephritis (IgA-GN) with impaired renal function [abstract]. Nephrology Dialysis Transplantation 1995;10(6):968.
  • Frascà GM, Martello M, Canova C, Isola E, Vangelista A, Bonomini V. Defibrotide treatment and disease progression in patients with IgA nephropathy and impaired renal function at diagnosis. Clinical Drug Investigation 1997;13(4):185-91. [EMBASE: 1997135783]
  • Frascà GM, Martello M, Sestigiani E, Canova C, Vangelista A, Bonomini V. Effects of defibrotide treatment in patients with IgA nephropathy and reduced renal function. Clinical Drug Investigation 1997;13(4):185-91. [MEDLINE: 8700366]
  • Frascà GM, Martello M, Sestigiani E, Canova C, Vangelista A, Bonomini V. Effects of defibrotide treatment in patients with IgA nephropathy and reduced renal function. Nephrology Dialysis Transplantation 1996;11(2):392-3. [MEDLINE: 8700366]
Ghorbani 2009 {published data only}
  • Ghorbani A, Aalamshah M, Shahbazian H, Ehsanpour A, Aref A. Randomized controlled trial of clopidogrel to prevent primary arteriovenous fistula failure in hemodialysis patients. Indian Journal of Nephrology 2009;19(2):57-61. [EMBASE: 2009390539]
Giustina 1998 {published data only}
  • Giustina A, Perini P, Desenzani P, Bossoni S, Ianniello P, Milani M, et al. Long-term treatment with the dual antithromboxane agent picotamide decreases microalbuminuria in normotensive type 2 diabetic patients. Diabetes 1998;47(3):423-30. [MEDLINE: 9519749]
Gonzalez 1995 {published data only}
  • Gonzalez MT, Castelao AM, Valles M, Cruzado JM, Mauri JM. Platelet antiaggregants (PA) could decrease the rate of progression of chronic renal failure (CRF) in diabetic patients (DP) treated previously with angiotensin converting enzyme inhibitors (ACEI) [abstract]. ISN XIII International Congress of Nephrology; 1995 Jul 2-6; Madrid (Spain). 1995:200.
Gröntoft 1985 {published data only}
  • Gröntoft KC, Mulec H, Gutierrez A, Olander R. Thromboprophylactic effect of ticlopidine in arteriovenous fistulas for haemodialysis. Scandinavian Journal of Urology & Nephrology 1985;19(1):55-7. [MEDLINE: 3895411]
Gröntoft 1998 {published data only}
  • Gröntoft K, Larsson R, Mulec H, Weiss LG, Dickinson JP. Ticlopidine in fistula surgery: double-blind comparison against placebo on the rate of early occlusion of arterio-venous fistulae [abstract]. 12th International Congress of Nephrology; 1993 Jun 13-18; Jerusalem (Israel). 1993:398.
  • Gröntoft KC, Larsson R, Mulec H, Weiss LG, Dickinson JP. Effects of ticlopidine in AV-fistula surgery in uremia. Fistula Study Group. Scandinavian Journal of Urology & Nephrology 1998;32(4):276-83. [MEDLINE: 9764456]
Harter 1979 {published data only}
HOT Study 2010 {published and unpublished data}
  • Hansson L, Zanchetti A, Carruthers SG, Dahlöf B, Elmfeldt D, Julius S, et al. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group. Lancet 1998;351(9118):1755-62. [MEDLINE: 9635947]
  • Jardine MJ, Ninomiya T, Perkovic V, Cass A, Turnbull F, Gallagher MP, et al. Aspirin is beneficial in hypertensive patients with chronic kidney disease: a post-hoc subgroup analysis of a randomized controlled trial. Journal of the American College of Cardiology 2010;56(12):956-65. [MEDLINE: 20828648]
  • Kolloch RE, Rahn KH. The Hypertension Optimal Treatment (HOT) study: Results of 12-month treatment related to age [Die 'Hyperyension Optimal Treatment' (HOT)-Studie: Behandlungsergebnisse nach Zwolfmonatiger Therapie in Abhangigkeit vom Alter]. Deutsche Medizinische Wochenschrift 1998;123(1-2):1-5. [MEDLINE: 9465848]
  • Ruilope LM, Salvetti A, Jamerson K, Hansson L, Warnold I, Wedel H, et al. Renal function and intensive lowering of blood pressure in hypertensive participants of the hypertension optimal treatment (HOT) study. Journal of the American Society of Nephrology 2001;12(2):218-25. [MEDLINE: 11158211]
IMPACT II Study 1997 {unpublished data only}
  • Randomised placebo-controlled trial of effect of eptifibatide on complications of percutaneous coronary intervention: IMPACT-II. Integrilin to Minimise Platelet Aggregation and Coronary Thrombosis-II. Lancet 1997;349(9063):1422-8. [MEDLINE: 9164315]
  • Mandak JS, Blankenship JC, Gardner LH, Berkowitz SD, Aguirre FV, Sigmon KN, et al. Modifiable risk factors for vascular access site complications in the IMPACT II trial of angioplasty with versus without eptifibatide. Integrilin to Minimize Platelet Aggregation and Coronary Thrombosis. Journal of the American College of Cardiology 1998;31(7):1518-24. [MEDLINE: 9626829]
Kaegi 1974 {published data only}
Kauffmann 1980 {published data only}
  • Kauffmann HM, Adams MB, Hebert LA, Walczak PM. Platelet inhibitors in human renal homotransplantation: randomized comparison of aspirin versus dipyridamole. Transplantation Proceedings 1980;12(2):311-4. [MEDLINE: 6771905]
Kaufman 2003 {published and unpublished data}
  • Kaufman JS, O'Connor TZ, Zhang JH, Cronin RE, Fiore LD, Ganz MB, et al. Randomized controlled trial of clopidogrel plus aspirin to prevent hemodialysis access graft thrombosis. Journal of the American Society of Nephrology 2003;14(9):2313-21. [MEDLINE: 12937308]
  • Kaufman JS, O’Connor TZ, Zhang JH, Cronin RE, Fiore LD, Ganz MB, et al. Combination aspirin plus clopidogrel in the prevention of hemodialysis access graft thrombosis [abstract]. Journal of the American Society of Nephrology 2001;12(Program & Abstracts):291A.
Khajehdehi 2002 {published data only}
  • Khajehdehi P, Roozbeh J, Mostafavi H. A comparative randomized and placebo-controlled short-term trial of aspirin and dipyridamole for overt type-2 diabetic nephropathy. Scandinavian Journal of Urology & Nephrology 2002;36(2):145-8. [MEDLINE: 12028688]
Kobayashi 1980 {published data only}
  • Kobayashi K, Maeda K, Koshikawa S, Kawaguchi Y, Shimizu N, Naito C. Antithrombotic therapy with ticlopidine in chronic renal failure patients on maintenance hemodialysis: a multicenter collaborative double blind study. Thrombosis Research 1980;20(2):255-61. [MEDLINE: 7209880]
Kooistra 1994 {published data only}
  • Kooistra MP, van Es A. Effects of low dose aspirin on thrombovascular accidents during treatment with rHuEpo: a multicentre, controlled, cross-over study [abstract]. Nephrology Dialysis Transplantation 1993;8:277.
  • Kooistra MP, van Es A, Marx JJ, Hertsig ML, Struyvenberg A. Low-dose aspirin does not prevent thrombovascular accidents in low-risk haemodialysis patients during treatment with recombinant human erythropoietin. Nephrology Dialysis Transplantation 1994;9(8):1115-20. [MEDLINE: 7800210]
Michie 1977 {published data only}
  • Michie DD, Wombolt DG. Use of sulfinpyrazone to prevent thrombus formation in arteriovenous fistulas and bovine grafts of patients on chronic hemodialysis. Current Therapeutic Research Clinical & Experimental 1977;22(1):196-204.
Middleton 1992 {published data only}
  • Middleton DA, Deichsel G. The prophylaxis of thrombosis in new arteriovenous dialysis shunts in the arm by low-dose acetylsalicylic acid and dipyridamole. Berlin, Germany: Boehringer Ingelheim. Internal report 1992.
Ogawa 2008 {published data only}
  • Ogawa S, Mori T, Nako K, Ishizuka T, Ito S. Reduced albuminuria with sarpogrelate is accompanied by a decrease in monocyte chemoattractant protein-1 levels in type 2 diabetes. Clinical Journal of the American Society of Nephrology: CJASN 2008;3(2):362-8. [MEDLINE: 18235151]
PLATO Study 2010 {published data only}
  • James S, Budaj A, Aylward P, Buck KK, Cannon CP, Cornel JH, et al. Ticagrelor versus clopidogrel in acute coronary syndromes in relation to renal function: results from the Platelet Inhibition and Patient Outcomes (PLATO) Trial. Circulation 2010;122(11):1056-67. [MEDLINE: 20805430]
PRISM-PLUS Study 2002 {published data only (unpublished sought but not used)}
  • Januzzi JL Jr, Snapinn SM, DiBattiste PM, Jang IK, Theroux P. Benefits and safety of tirofiban among acute coronary syndrome patients with mild to moderate renal insufficiency: results from the Platelet Receptor Inhibition in Ischemic Syndrome Management in Patients Limited by Unstable Signs and Symptoms (PRISM-PLUS) trial. Circulation 2002;105(20):2361-6. [MEDLINE: 12021221]
PURSUIT Study 1998 {unpublished data only}
  • Inhibition of platelet glycoprotein IIb/IIIa with eptifibatide in patients with acute coronary syndromes. The PURSUIT Trial Investigators. Platelet Glycoprotein IIb/IIIa in Unstable Angina: Receptor Suppression Using Integrilin Therapy. New England Journal of Medicine 1998;339(7):436-43. [MEDLINE: 9705684]
Quarto Di Palo 1991 {published data only}
  • Quarto Di Palo F, Elli A, Rivolta R, Parenti M, Palazzi P, Zanussi C. Prevention of chronic cyclosporine nephrotoxicity in renal transplantation by picotamide. Transplantation Proceedings 1991;23(1 Pt 2):969-71. [MEDLINE: 1989347]
RAPPORT Study 1998 {unpublished data only}
  • Brener SJ, Barr LA, Burchenal JE, Katz S, George BS, Jones AA, et al. Randomized, placebo-controlled trial of platelet glycoprotein IIb/IIIa blockade with primary angioplasty for acute myocardial infarction. ReoPro and Primary PTCA Organization and Randomized Trial (RAPPORT) Investigators. Circulation 1998;98(8):734-41. [MEDLINE: 9727542]
Schulze 1990 {published data only}
  • Schulze von R, Langkopf B, Sziegoleit W. The effect of dipyridamole on the results of allogenic kidney transplantation [Der Einfluss von Dipyridamol auf die Ergebnisse der allogenen Nieren-transplantation]. Zeitschrift für Urologie und Nephrologie 1990;83(5):255-9. [MEDLINE: 2203215]
Sreedhara 1994 {published data only}
  • Sreedhara R, Himmelfarb J, Lazarus JM, Hakim RM. Anti-platelet therapy in graft thrombosis: results of a prospective, randomized, double blind study. Kidney International 1994;45(5):1477-83. [MEDLINE: 8072261]
  • Sreedhara R, Himmelfarb J, Lazarus JM, Hakim RM. Antiplatelet therapy in expanded polytetrafluoroethylene (EPTFE) graft thrombosis: results of a randomized double blind study [abstract]. Journal of the American Society of Nephrology 1993;4(Program & Abstracts):388.
STOP Study 1995 {published and unpublished data}
  • Mileti M, De PG, Bacchi M, Ogliari V, Pecchini F, Bufano G, et al. A trial to evaluate the efficacy of picotamide in preventing thrombotic occlusion of the vascular access in hemodialysis patients. Journal of Nephrology 1995;8(2):167-72. [EMBASE: 1995200634]
Taber 1992 {published data only}
  • Taber T, Maikranz P, Haag B, Dilley R, Gaylord G. Hemodialysis vascular graft stenosis may be altered by low-molecular weight dextran (LMD), but not by aspirin (ASA) [abstract]. Journal of the American Society of Nephrology 1992;3(3):397.
TARGET Study 2001 {published and unpublished data}
  • Berger PB, Best PJ, Topol EJ, White J, DiBattiste PM, Chan AW, et al. The relation of renal function to ischemic and bleeding outcomes with 2 different glycoprotein IIb/IIIa inhibitors: the do Tirofiban and ReoPro Give Similar Efficacy Outcome (TARGET) trial. American Heart Journal 2005;149(5):869-75. [MEDLINE: 15894970]
  • Topol EJ, Moliterno DJ, Herrmann HC, Powers ER, Grines CL, Cohen DJ, et al. Comparison of two platelet glycoprotein IIb/IIIa inhibitors, tirofiban and abciximab, for the prevention of ischemic events with percutaneous coronary revascularization. New England Journal of Medicine 2001;344(25):1888-94. [MEDLINE: 11419425]
TRITON-TIMI 38 2007 {unpublished data only}
UK-HARP-I Study 2005 {published and unpublished data}
  • Baigent C, Landray M, Leaper C, Altmann P, Armitage J, Baxter A, et al. First United Kingdom Heart and Renal Protection (UK-HARP-I) study: biochemical efficacy and safety of simvastatin and safety of low-dose aspirin in chronic kidney disease. American Journal of Kidney Diseases 2005;45(3):473-84. [MEDLINE: 15754269]
  • Baigent C, UK-HARP Steering Committee. Efficacy and safety of simvastatin and safety of low-dose aspirin among patients with chronic kidney disease: final results of the first UK-heart and renal protection (UK-HARP-I) study [abstract]. Journal of the American Society of Nephrology 2002;13(Program & Abstracts):437A.
Zäuner 1994 {published data only}
  • Zäuner I, Böhler J, Braun N, Grupp C, Heering P, Schollmeyer P. Effect of aspirin and dipyridamole on proteinuria in idiopathic membranoproliferative glomerulonephritis: a multicentre prospective clinical trial. Nephrology Dialysis Transplantation 1994;9(6):619-22. [MEDLINE: 7970086]

References to studies excluded from this review

  1. References to studies included in this review
  2. References to studies excluded from this review
  3. References to ongoing studies
  4. Additional references
  5. References to other published versions of this review
CAPRIE Study 1996 {published data only}
  • CAPRIE Steering Committee. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee. Lancet 1996;348(9038):1329-39. [MEDLINE: 8918275]
  • Harker LA, Boissel JP, Pilgrim AJ, Gent M. Comparative safety and tolerability of clopidogrel and aspirin: results from CAPRIE. CAPRIE Steering Committee and Investigators. Clopidogrel versus aspirin in patients at risk of ischaemic events. Drug Safety 1999;21(4):325-35. [MEDLINE: 10514023]
Caravaca 1995 {published data only}
  • Caravaca F, Lopez-Minguez JR, Arrobas M, Cubero J, Pizarro JL, Cid MC, et al. Haemodynamic changes induced by the correction of anaemia by erythropoietin: role of antiplatelet therapy. Nephrology Dialysis Transplantation 1995;10(9):1720-4. [MEDLINE: 8559495]
Chew 2005 {published data only}
  • Chew DP, Lincoff AM, Gurm H, Wolski K, Cohen DJ, Henry T, et al. Bivalirudin versus heparin and glycoprotein IIb/IIIa inhibition among patients with renal impairment undergoing percutaneous coronary intervention (a subanalysis of the REPLACE-2 trial). American Journal of Cardiology 2005;95(5):581-5. [MEDLINE: 15721095]
Dmoszynska 1990 {published data only}
  • Dmoszynska-Giannopoulou A, Janicka L, Sokolowska B, Ksiazek A, Orlowska G, Janicki K. The effect of sulphinpyrazone and alpha-tocopherol on platelet activation and function in haemodialysed patients. International Urology & Nephrology 1990;22(6):561-6. [MEDLINE: 2093696]
EXCITE Study 2008 {published data only}
  • Mercado N, Brugts JJ, Ix JH, Shlipak MG, Dixon SR, Gersh BJ, et al. Usefulness of proteinuria as a prognostic marker of mortality and cardiovascular events among patients undergoing percutaneous coronary intervention (data from the Evaluation of Oral Xemilofiban in Controlling Thrombotic Events [EXCITE] trial). American Journal of Cardiology 2008;102(9):1151-5. [MEDLINE: 18940282]
Gorter 1998 {published data only}
  • Gorter JW. Preventive treatment of patients after non-disabling cerebral ischaemia of presumed arterial origin: Comparative randomized study with intensive anticoagulant therapy or aspirin treatment [Preventieve behandeling van patienten na niet-invaliderende cerebrale ischemie door vermoedelijk arteriele oorzaak: Vergelijkend, gerandomiseerd onderzoek met intensieve antistollingstherapie of behandeling met acetylsalicylzuur]. Nederlands Tijdschrift voor Geneeskunde 1998;142(6):306-12. [EMBASE: 1998075400]
Hayden 2002 {published data only}
  • Hayden M, Pignone M, Phillips C, Mulrow C. Aspirin for the primary prevention of cardiovascular events: a summary of the evidence for the U.S. Preventive Services Task Force. Annals of Internal Medicine 2002;136(2):161-72. [MEDLINE: 11790072]
Huang 2009 {published data only}
  • Huang J. Investigation of platelet function and aspirin resistance in chronic dialysis patient. Available at http://www.clinicaltrials.gov/ct2/show/NCT01045785 (accessed 24 December 2012).
Janicki 2003 {published data only}
  • Janicki K, Bojarska-Szmygin A, Pietura R, Janicka L. Preventive effects of ticlopidine on the incidence of late AV fistula thrombosis complications in haemodialyses patients. Annales Universitatis Mariae Curie-Sklodowska - Sectio d - Medicina 2003;58(1):215-8. [MEDLINE: 15314987]
Kamper 1997 {published data only}
  • Kamper AM, Lins RL, Zachee P, Van Bergen S, Hosten S, Daelemans R. Safety of combining ticlopidine with nadroparin in the routine treatment of chronic hemodialysis patients. Nephron 1997;77(4):484-5. [MEDLINE: 9434075]
Kim 2009 {published data only}
  • Kim KM, Kim HW, Lee JH, Chang JW, Park JS, Kim SB. Effects of beraprost sodium, an oral prostaglandin i2 analog, on hemostatic factors and inflammation in chronic peritoneal dialysis patients. Peritoneal Dialysis International 2009;29(2):178-81. [MEDLINE: 19293355]
Lang 1998 {published data only}
  • Lang J, Cao H, Wei A. Comparative study on effect of Panax notoginseng and ticlid in treating early diabetic nephropathy. Zhongguo Zhong Xi Yi Jie He Za Zhi Zhongguo Zhongxiyi Jiehe Zazhi [Chinese Journal of Integrated Traditional and Western Medicine] 1998;18(12):727-9. [MEDLINE: 11475719]
Lee 1997 {published data only}
Lindsay 1972 {published data only}
  • Lindsay RM, Ferguson D, Prentice CR, Burton JA, McNicol GP. Reduction of thrombus formation on dialyser membranes by aspirin and RA 233. Lancet 1972;2(7790):1287-90. [MEDLINE: 4117813]
Minakata 1998 {published data only}
  • Minakata T, Yonemoto S, Nomura K, Yoshida H. Antiplatelet drugs in diabetic hemodialysis patients: comparison of aspirin vs ticlopidine hydrochloride [abstract]. 35th Congress, European Renal Association, European Dialysis and Transplantation Association; Rimini (Italy). 1998:240.
Movchan 2001 {published data only}
  • Movchan EA, Chuprova AV, Tov NL, Vol'vich NV. Desaggregation therapy of acute glomerulonephritis. Klinicheskaia Meditsina 2001;79(12):44-7. [MEDLINE: 11840813]
NITER Study 2005 {published data only}
  • Scarpioni R, Michieletti E, Cristinelli L, Ugolotti U, Scolari F, Venturelli C, et al. Atherosclerotic renovascular disease: medical therapy versus medical therapy plus renal artery stenting in preventing renal failure progression: the rationale and study design of a prospective, multicenter and randomized trial (NITER). Journal of Nephrology 2005;18(4):423-8. [MEDLINE: 16245247]
Perkovic 2004 {published data only}
  • Perkovic V, Nicholls KM, Foreman A, Becker GJ. A randomised controlled trial of cardiovascular risk factor modification in end stage renal failure [abstract]. Nephrology 2004;9(Suppl 1):A16.
  • Perkovic V, Nicholls KM, Foreman A, Walker RG, Becker GJ. A randomised controlled trial of cardiovascular risk factor modification in end stage kidney disease [abstract]. Journal of the American Society of Nephrology 2004;15:377A-8A.
Peto 1988 {published data only}
  • Peto R, Gray R, Collins R, Wheatley K, Hennekens C, Jamrozik K, et al. Randomised trial of prophylactic daily aspirin in British male doctors. British Medical Journal Clinical Research Ed. 1988;296(6618):313-6. [MEDLINE: 3125882]
Physician Health Study 1989 {published data only}
  • Physicians' Health Study Research Group. Final report on the aspirin component of the ongoing Physicians' Health Study. Steering Committee of the Physicians' Health Study Research Group. New England Journal of Medicine 1989;321(3):129-35. [MEDLINE: 2664509]
Physician Health Study 1998 {published data only}
  • Physician Health Study. Thrombosis prevention trial: randomised trial of low-intensity oral anticoagulation with warfarin and low-dose aspirin in the primary prevention of ischaemic heart disease in men at increased risk. The Medical Research Council's General Practice Research Framework. Lancet 1998;351(9098):233-41. [MEDLINE: 9457092]
RAS-CAD Study 2009 {published data only}
  • Marcantoni C, Zanoli L, Rastelli S, Tripepi G, Matalone M, Di Landro D, et al. Stenting of renal artery stenosis in coronary artery disease (RAS-CAD) study: a prospective, randomized trial. Journal of Nephrology 2009;22(1):13-6. [MEDLINE: 19229814]
RESIST Study 2008 {published data only}
Rubin 1982 {published data only}
Salter 1984 {published data only}
  • Salter MC, Crow MJ, Donaldson DR, Roberts TG, Rajah SM, Davison AM. Prevention of platelet deposition and thrombus formation on hemodialysis membranes: a double-blind randomized trial of aspirin and dipyridamole. Artificial Organs 1984;8(1):57-61. [MEDLINE: 6703927]
STENO-2 Study 2008 {published data only}
  • Gaede P, Lund-Andersen H, Parving HH, Pedersen O. Effect of a multifactorial intervention on mortality in type 2 diabetes. New England Journal of Medicine 2008;358(6):580-91. [MEDLINE: 18256393]
Swan 1995 {published data only}
  • Halstenson CE, Swan SK, Collins AJ, Ellefson J, Parr K, Blue J, et al. Pharmacologic profile of diaspirin crosslinked hemoglobin (DCLHB) in hemodialysis (HD) patients [abstract]. Journal of the American Society of Nephrology 1994;5(3):451.
  • Swan SK, Halstenson CE, Collins AJ, Colburn WA, Blue J, Przybelski RJ. Pharmacologic profile of diaspirin cross-linked hemoglobin in hemodialysis patients. American Journal of Kidney Diseases 1995;26(6):918-23. [MEDLINE: 7503066]
  • Swan SK, Halstenson CE, Collins AJ, Ellefson J, Parr K, Blue J, et al. Pharmacodynamic and pharmacokinetic parameters of diaspirin cross-linked hemoglobin (DCLHB) in hemodialysis (HD) patients [abstract]. ISN XIII International Congress of Nephrology; 1995 Jul 2-6; Madrid (Spain). 1995:559.
SYMPHONY II 2005 {published data only}
  • Reddan DN, Szczech L, Bhapkar MV, Moliterno DJ, Califf RM, Ohman EM, et al. Renal function, concomitant medication use and outcomes following acute coronary syndromes. Nephrology Dialysis Transplantation 2005;20(10):2105-12. [MEDLINE: 16030030]
SYMPHONY I Study 2000 {published data only (unpublished sought but not used)}
  • Comparison of sibrafiban with aspirin for prevention of cardiovascular events after acute coronary syndromes: a randomised trial. The SYMPHONY Investigators. Sibrafiban versus Aspirin to Yield Maximum Protection from Ischemic Heart Events Post-acute Coronary Syndromes. Lancet 2000;355(9201):337-45. [MEDLINE: 10665552]
Trimarchi 2006 {published data only}
Van Der Zaag 2001 {published data only}
  • Van Der Zaag ES, Legemate DA, Tangelder MJ, Algra A, Lawson JA, Eikelboom BC. Prevention of occlusions after bypass surgery with anticoagulant agents or acetylsalicylic acid: a randomised comparison. Nederlands Tijdschrift voor Geneeskunde 2001;145(36):1765. [EMBASE: 2001320548]
Vienken 1996 {published data only}
  • Vienken JA. Thromboxane generation by dialysis membranes is controlled by aspirin administration [abstract]. Nephrology Dialysis Transplantation 1996;11:1472.
Yoshikawa 1999 {published data only}
  • Yoshikawa N, Ito H. Combined therapy with prednisolone, azathioprine, heparin-warfarin, and dipyridamole for paediatric patients with severe IgA nephropathy - is it relevant for adult patients?. Nephrology Dialysis Transplantation 1999;14(5):1097-9. [MEDLINE: 10344344]
Zibari 1995 {published data only}
  • Zibari GB, Gadallah MF, Landreneau MD, McMillian R, Bridges R, Costley K, et al. The efficacy and complications of aspirin versus heparin in postoperative prophylaxis against thrombosis in newly placed hemodialysis access [abstract]. Journal of the American Society of Nephrology 1995;6(3):507.

References to ongoing studies

  1. References to studies included in this review
  2. References to studies excluded from this review
  3. References to ongoing studies
  4. Additional references
  5. References to other published versions of this review
FAVOURED Trial {published data only}
  • Irish A, Dogra G, Mori T, Beller E, Heritier S, Hawley C, et al. Preventing AVF thrombosis: the rationale and design of the Omega-3 fatty acids (Fish Oils) and Aspirin in Vascular access OUtcomes in REnal Disease (FAVOURED) study. BMC Nephrology 2009;10:1. [MEDLINE: 19159453]
  • Irish A, FAVOURED Study Group. High rate of screening failure in the FAVOURED study [abstract]. Nephrology 2009;14(Suppl 1):A45.
NCT01198379 {published data only}
  • Taipei Veterans General Hospital, Taiwan. Efficacy of monitoring of aspirin responsiveness in the prevention of cardiovascular events and decrease in bleeding complications in patients with end-stage kidney disease undergoing hemodialysis. Available at http://clinicaltrials.gov/ct2/show/NCT01198379 (accessed 12 November 2012).

Additional references

  1. References to studies included in this review
  2. References to studies excluded from this review
  3. References to ongoing studies
  4. Additional references
  5. References to other published versions of this review
Aakhus 1999
Amann 2003
Anavekar 2004
  • Anavekar NS, McMurray JJ, Velazquez EJ, Solomon SD, Kober L. Rouleau JL, et al. Relation between renal dysfunction and cardiovascular outcomes after myocardial infarction. New England Journal of Medicine 2004;351(13):1285-95. [MEDLINE: 15385655]
ANZDATA 2009
  • Australia, New Zealand Dialysis, Transplant Registry. The 32nd Annual Report 2009 Report - Data to 2008. http://www.anzdata.org.au/v1/report_2009.html (accessed 12 November 2012).
ATT 2002
  • Antithrombotic Trialists' Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 2002;324(7329):71-86. [MEDLINE: 11786451]
ATT 2009
  • Antithrombotic Trialists' (ATT) Collaboration. Baigent C, Blackwell L, Collins R, Emberson J, Godwin J, et al. Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials. Lancet 2009;373(9678):1849-60. [MEDLINE: 19482214]
AusDiab 2003
  • Chadban SJ, Briganti EM, Kerr PG, Dunstan DW, Welborn TA, Zimmet PZ, et al. Prevalence of kidney damage in Australian adults: The AusDiab kidney study. Journal of the American Society of Nephrology 2006;14(7 Suppl 2):S131-8. [MEDLINE: 12819318]
Berger 2003
  • Berger AK, Duval S, Krumholz HM. Aspirin, beta-blocker, and angiotensin-converting enzyme inhibitor therapy in patients with end-stage renal disease and an acute myocardial infarction. Journal of the American College of Cardiology 2003;42(2):201-8. [MEDLINE: 12875751]
Best 2008
  • Best PJ, Steinhubl SR, Berger PB, Dasgupta A, Brennan DM, Szczech LA, et al. The efficacy and safety of short- and long-term dual antiplatelet therapy in patients with mild or moderate chronic kidney disease: results from the Clopidogrel for the Reduction of Events During Observation (CREDO) trial. American Heart Journal 2008;155(4):687-93. [MEDLINE: 18371477]
Bonomini 1986
CARI 2000
  • Caring for Australasians with Renal Impairment (CARI). Vascular access. http://www.cari.org.au/dialysis_va_list_published.php (accessed 12 November 2012).
Casas 2005
  • Casas JP, Chua W, Loukogeorgakis S, Vallance P, Smeeth L, Hingorani AD, et al. Effect of inhibitors of the renin-angiotensin system and other antihypertensive drugs on renal outcomes: systematic review and meta-analysis. Lancet 2005;366(9502):2026-33. [MEDLINE: 16338452]
Coleman 2010
Collins 2003
Curtis 2005
de Jager 2009
  • de Jager DJ, Grootendorst DC, Jager KJ, van Dijk PC, Tomas LM, Ansell D, et al. Cardiovascular and noncardiovascular mortality among patients starting dialysis. JAMA 2009;302(16):1782-9. [MEDLINE: 19861670]
Dikow 2005
Fields 2004
Foley 1995
Fort 2005
  • Fort J. Chronic renal failure: a cardiovascular risk factor. Kidney International - Supplement 2005;99:S25-9. [MEDLINE: 16336573]
Go 2004
GRADE 2011
  • GRADE Working Group. Grading of Recommendations Assessment, Development and Evaluation (GRADE). http://www.gradeworkinggroup.org/index.htm.
Higgins 2003
Higgins 2011
  • Higgins JP, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.
Holden 2008
Kasiske 2000
Kaw 2006
KDOQI 2005
  • National Kidney Foundation. KDOQI clinical practice guidelines for cardiovascular disease in dialysis patients. http://www.kidney.org/professionals/kdoqi/guidelines_cvd/guide3.htm (accessed 12 November 2012).
Keith 2004
  • Keith DS, Nichols GA, Gullion CM, Brown JB, Smith DH. Longitudinal follow-up and outcomes among a population with chronic kidney disease in a large managed care organization. Archives of Internal Medicine 2004;164(6):659-63. [MEDLINE: 15037495]
Koren-Morag 2006
Mann 2001
  • Mann JF, Gerstein HC, Pogue J, Bosch J, Yusuf S. Renal insufficiency as a predictor of cardiovascular outcomes and the impact of ramipril: the HOPE randomized trial. Annals of Internal Medicine 2001;134(8):629-36. [MEDLINE: 11304102]
McCullough 2002
  • McCullough PA, Sandberg KR, Borzak S, Hudson MP, Garg M, Manley HJ. Benefits of aspirin and beta-blockade after myocardial infarction in patients with chronic kidney disease. American Heart Journal 2002;144(2):226-32. [MEDLINE: 12177638]
Mokdad 2003
Mosenkis 2004
  • Mosenkis A, Berns JS. Use of low molecular weight heparins and glycoprotein IIb/IIIa inhibitors in patients with chronic kidney disease. Seminars in Dialysis 2004;17(5):411-5. [MEDLINE: 15461751]
NHANES 2010
  • National Health and Nutrition Examination Survey. http://www.cdc.gov/nchs/nhanes.htm (accessed 12 November 2012).
Norris 2006
  • Norris K, Bourgoigne J, Gassman J, Hebert L, Middleton J, Phillips RA, et al. Cardiovascular outcomes in the African American Study of Kidney Disease and Hypertension (AASK) Trial. American Journal of Kidney Diseases 2006;48(5):739-51. [MEDLINE: 17059993]
Ojo 2000
Osborn 2008
Palmer 2007
  • Palmer SC, McGregor DO, Macaskill P, Craig JC, Elder GJ, Strippoli GF. Meta-analysis: vitamin D compounds in chronic kidney disease. Annals of Internal Medicine 2007;147(12):840-53. [MEDLINE: 18087055]
Remppis 2008
Remuzzi 1988
Renal Association 2010
  • Renal Association. Cardiovascular disease in CKD. http://www.renal.org/Clinical/GuidelinesSection/CardiovascularDiseaseInCKD.aspx#Rationale3 (accessed 12 November 2012).
Ruilope 2001
  • Ruilope LM, Salvetti A, Jamerson K, Hansson L, Warnold I, Wedel H, et al. Renal function and intensive lowering of blood pressure in hypertensive participants of the hypertension optimal treatment (HOT) study. Journal of the American Society of Nephrology 2001;12(2):218-25. [MEDLINE: 11158211]
Sarnak 2003
  • Sarnak MJ, Levey AS, Schoolwerth AC, Coresh J, Culleton B, Hamm LL, et al. Kidney disease as a risk factor for development of cardiovascular disease: a statement from the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention. Hypertension 2003;42(5):1050-65. [MEDLINE: 14604997]
Scheen 2008
Song 2003
Sterne 2011
  • Sterne JA, Egger M, Moher D (editors). Chapter 10: Addressing reporting biases. In: Higgins JP, Green S (editors). Cochrane Handbook for Systematic Reviews of Intervention Version 5.1.0 [March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.
Taji 2006
  • Taji Y, Kuwahara T, Shikata S, Morimoto T. Meta-analysis of antiplatelet therapy for IgA nephropathy. Clinical & Experimental Nephrology 2006;10(4):268-73. [MEDLINE: 17186331]
USRDS 2010
  • US Renal Data System. USRDS 2010 Annual Data Report. Atlas of Chronic Kidney Disease and End-Stage Renal Disease in the United States, National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD. http://www.usrds.org/atlas10.aspx (accessed 12 November 2012).
Wattanakit 2008
Weiner 2004a
  • Weiner DE, Tighiouart H, Amin MG, Stark PC, MacLeod B, Griffith JL, et al. Chronic kidney disease as a risk factor for cardiovascular disease and all-cause mortality: a pooled analysis of community-based studies. Journal of the American Society of Nephrology 2004;15(5):1307-15. [MEDLINE: 15100371]
Weiner 2004b
  • Weiner DE, Tighiouart H, Stark PC, Amin MG, MacLeod B, Griffith JL, et al. Kidney disease as a risk factor for recurrent cardiovascular disease and mortality. American Journal of Kidney Diseases 2004;44(2):198-206. [MEDLINE: 15264177]
Weiner 2006
  • Weiner DE, Tabatabai S, Tighiouart H, Elsayed E, Bansal N, Griffith J, et al. Cardiovascular outcomes and all-cause mortality: exploring the interaction between CKD and cardiovascular disease. American Journal of Kidney Diseases 2006;48(3):392-401. [MEDLINE: 16931212]
Zwaginga 1991
  • Zwaginga JJ, IJsseldijk MJ, de Groot P G, Vos J, de Bos Kuil RL, Sixma JJ. Defects in platelet adhesion and aggregate formation in uremic bleeding disorder can be attributed to factors in plasma. Arteriosclerosis & Thrombosis 1991;11(3):733-44. [MEDLINE: 2029508]

References to other published versions of this review

  1. References to studies included in this review
  2. References to studies excluded from this review
  3. References to ongoing studies
  4. Additional references
  5. References to other published versions of this review
Palmer 2012
  • Palmer SC, Di Micco L, Razavian M, Craig JC, Ravani P, Perkovic V, et al. Antiplatelet therapy to prevent hemodialysis vascular access failure: systematic review and meta-analysis. American Journal of Kidney Diseases 2013;61(1):112-22. [MEDLINE: 23022428]
Razavian 2010
  • Razavian M, Di Micco L, Palmer SC, Craig JC, Perkovic V, Zoungas S, et al. Antiplatelet agents for chronic kidney disease. Cochrane Database of Systematic Reviews 2010, Issue 11. [DOI: 10.1002/14651858.CD008834]